Topical delivery of methotrexate via skin pretreated with physical enhancement techniques: Low-fluence erbium:YAG laser and electroporation

Lasers in Surgery and Medicine

Volumn 40, Issue 7, 2008, Pages 468-476

  Lee, Woan Ruoh ^a,b   Shen, Shin Chuan ^b   Fang, Chia Lang ^c   Zhuo, Rou Zi ^d   Fang, Jia You ^d  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Electroporation; Er:YAG laser; Hyperproliferation; Methotrexate; Topical delivery

Indexed keywords

METHOTREXATE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; ELECTROPORATION; EPIDERMIS HYPERPLASIA; ERBIUM YAG LASER; EVALUATION; FEMALE; HYDROPHILICITY; IN VITRO STUDY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; NUDE MOUSE; PERMEABILITY BARRIER; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SKIN PERMEABILITY; TECHNIQUE;

ADMINISTRATION, TOPICAL; ANIMALS; DERMATOLOGIC AGENTS; ELECTROPORATION; FEMALE; LASER THERAPY, LOW-LEVEL; LASERS, SOLID-STATE; METHOTREXATE; MICE; MICE, NUDE; SKIN;

EID: 51849163223     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.20655     Document Type: Article

References (38)

1. Witman PM. Topical therapies for localized psoriasis. Mayo Clin Proc 2001;76:943-949.
2. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-873.
3. Eskicirak B, Zemheri E, Cerkezoglu A. The treatment of psoriasis vulgaris: 1% topical methotrexate gel. Int J Dermatol 2006;45:965-969.
4. Su YH, Fang JY. Drug delivery and formulations for the topical treatment of psoriasis. Expert Opin Drug Deliv 2008; 5:235-249.
5. Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: Implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65:168-173.
6. Rosenberg P, Urwitz H, Johannesson A, Ros A, Lindholm J, Kinnman N, Hultcrantz R. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007;46:1111-1118.
7. Alvarez-Figueroa MJ, Blanco-Méndez J. Transdermal delivery of methotrexate: Iontophoretic delivery from hydrogels and passive delivery from microemulsions. Int J Pharm 2001; 215:57-65.
8. Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Release 2007;123:148-154.
9. Lee WR, Shen SC, Wang KH, Hu CH, Fang JY. Lasers and microdermabrasion enhance and control topical delivery of vitamin C. J Invest Dermatol 2003;121:1118-1125.
10. Fang JY, Lee WR, Shen SC, Fang YP, Hu CH. Enhancement of topical 5-aminolevulinic acid delivery by erbium:YAG laser and microdermabrasion: A comparison to iontophoresis and electroporation. Br J Dermatol 2004;151:132-140.
11. Fang JY, Lee WR, Shen SC, Wang HY, Fang CL, Hu CH. Transdermal delivery of macromolecules by erbium:YAG laser. J Control Release 2004;100:75-85.
12. Lee WR, Shen SC, Liu CJ, Fang CL, Hu CH, Fang JY. Erbium:YAG laser-mediated oligonucleotide and DNA delivery via the skin: An animal study. J Control Release 2006; 115:344-353.
13. Yun PL, Tachihara R, Anderson RR. Efficacy of erbium: Yttrium-aluminum-garnet laser-assisted delivery of topical anesthetic. J Am Acad Dermatol 2002;47:542-547.
14. Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: Current and future prospects. Drug Deliv 2006;13:175-187.
15. Demerjian M, Mao MQ, Choi EH, Brown BE, Crumrine D, Chang S, Mauro T, Elias PM, Feingold KR. Topical treatment with thiazolidinediones, activators of peroxisome proliferators-activated receptor-γ, normalizes epidermal homeostasis in a murine hyperproliferative disease model. Exp Dermatol 2006;15:154-160.
16. Sutton L, Swinehart JM, Cato A, Kaplan AS. A clinical study to determine the efficacy and safety of 1% methotrexate/ Azone® (MAZ) gel applied topically once daily in patients with psoriasis vulgaris. Int J Dermatol 2001;40:464-467.
17. Godin B, Touitou E. Transdermal skin delivery: Predictions for humans from in vivo, ex vivo and animal models. Adv Drug Deliv Rev 2007;59:1152-1161.
18. Catz P, Friend D. Transdermal delivery of levonorgestrel: VIII. Effect of enhancers on rat skin, hairless mouse skin, hairless guinea pig skin, and human skin. Int J Pharm 1990; 58:93-102.
19. Fang JY, Fang CL, Sung KC, Chen HY. Effect of low frequency ultrasound on the in vitro percutaneous absorption of clobetasol 17-propionate. Int J Pharm 1999;191:33-42.
20. Doukas AG, Kollias N. Transdermal drug delivery with a pressure wave. Adv Drug Deliv Rev 2004;56:559-579.
21. Lee WR, Shen SC, Wang KH, Hu CH, Fang JY. The effect of laser treatment on skin to enhance and control transdermal delivery of 5-fluorouracil. J Pharm Sci 2002;91:1613-1626.
22. Manaloto RMP, Alster T. Erbium:YAG laser resurfacing for refractory melasma. Dermatol Surg 1999;25:121-123.
23. Lee S, McAuliffe DJ, Flotte TJ, Kollias N, Doukas AG. Photomechanical transcutaneous delivery of macromolecules. J Invest Dermatol 1998;111:925-929.
24. Lee S, McAuliffe DJ, Flotte TJ, Kollias N, Doukas AG. Photomechanical transdermal delivery: The effect of laser confinement. Laser Surg Med 2001;28:344-347.
25. Ogura M, Sato S, Nakanishi K, Uenoyama M, Kiyozumi T, Saitoh D, Ikeda T, Ashida H, Obara M. In vivo targeted gene transfer in skin by the use of laser-induced stress waves. Laser Surg Med 2004;34:242-248.
26. Makki S, Muret P, Saïd AM, Bassignot P, Humbert P, Agache P, Millet J. Percutaneous absorption of three psoralens commonly used in therapy: Effect of skin occlusion (in vitro study). Int J Pharm 1996;133:245-252.
27. Banga AK, Prausnitz MR. Assessing the potential of skin electroporation for the delivery of protein- and gene-based drugs. Trends Biotechnol 1998;16:408-412.
28. Trotta M, Peira E, Carlotti ME, Gallarate M. Deformable liposomes for dermal administration of methotrexate. Int J Pharm 2004;270:119-125.
29. Sung KC, Fang JY, Wang JJ, Hu OP. Transdermal delivery of nalbuphine and its prodrugs by electroporation. Eur J Pharm Sci 2003;18:63-70.
30. Denet A, Vanbever R, Préat V. Skin electroporation for transdermal and topical delivery. Adv Drug Deliv Rev 2004; 56:659-674.
31. Narasimha Murthy S, Sen A, Zhao YL, Hui SW. pH influences the postpulse permeability state of skin after electroporation. J Control Release 2003;93:49-57.
32. Baba M, Bal N. Efficacy and safety of the short-pulse erbium:YAG laser in the treatment of acquired melanocytic nevi. Dermatol Surg 2006;32:256-260.
33. Medi BM, Singh J. Skin targeted DNA vaccine delivery using electroporation in rabbits II. Safety Int J Pharm 2006;308: 61-68.
34. Nickoloff BJ, Bonish B, Huang BB, Porcelli SA. Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J Derm atol Sci 2000;24:212-225.
35. Gniadecki R. Regulation of keratinocyte proliferation. Gen Pharmacol 1998;30:619-622.
36. Alvarez-Figueroa MJ, Delgado-Charro MB, Blanco-Méndez J. Passive and iontophoretic transdermal penetration of methotrexate. Int J Pharm 2001;212:101-107.
37. Prasad R, Koul V, Anand S, Khar RK. Effect of DC/mDC iontophoresis and terpenes on transdermal permeation of methotrexate: In vitro study. Int J Pharm 2007;333:70-78.
38. Wong TW, Zhao YL, Sen A, Hui SW. Pilot study of topical delivery of methotrexate by electroporation. Br J Dermatol 2005;152:524-530.